

North Central Cancer Treatment Group

N0572: A Phase I/II Study of Sorafenib and CCI-779 in Patients with Recurrent Glioblastoma

Revised Status Change – May 21, 2008

NOTICE OF STATUS CHANGE

The Phase II dose has been reduced per section 7.21. The Phase II dose level, as referenced in section 7.22 and 7.23, has been reduced to dose level -1 (Sorafenib dose 200mg bid, CCI-779 dose 20mg) shown in the table in section 7.12 effective Wednesday, May 21, 2008.

Please retain this notice with the protocol.